Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Melanoma following treatment with alemtuzumab for multiple sclerosis.

× No keyword cloud information.

9 in total

1. Association of melanoma and natalizumab therapy in the Italian MS population: a second case report.

Authors: A Laroni; M Bedognetti; A Uccelli; E Capello; G L Mancardi
Journal: Neurol Sci Date: 2010-11-05 Impact factor: 3.307

2. Detection of a new melanoma in a patient treated with fingolimod.

Authors: Yves Michiels; Olivier Bugnon; Jean-François Michiels; Sophie Mazellier
Journal: BMJ Case Rep Date: 2019-04-29

3. Cancer and multiple sclerosis in the era of disease-modifying treatments.

Authors: Christine Lebrun; Patrick Vermersch; David Brassat; Gilles Defer; Lucien Rumbach; Pierre Clavelou; Marc Debouverie; Jérôme de Seze; Sandrine Wiertlevsky; Olivier Heinzlef; Ayman Tourbah; Agnes Fromont; Marc Frenay
Journal: J Neurol Date: 2011-02-04 Impact factor: 4.849

Review 4. Treatment of multiple sclerosis: current concepts and future perspectives.

Authors: Dorothea Buck; Bernhard Hemmer
Journal: J Neurol Date: 2011-06-03 Impact factor: 6.682

Review 5. Cancer Risk in Patients with Multiple Sclerosis: Potential Impact of Disease-Modifying Drugs.

Authors: Christine Lebrun; Fanny Rocher
Journal: CNS Drugs Date: 2018-10 Impact factor: 5.749

Review 6. Alemtuzumab for the treatment of multiple sclerosis.

Authors: Mark D Willis; Neil P Robertson
Journal: Ther Clin Risk Manag Date: 2015-03-31 Impact factor: 2.423

Review 7. Alemtuzumab for Multiple Sclerosis.

Authors: Mark D Willis; Neil P Robertson
Journal: Curr Neurol Neurosci Rep Date: 2016-09 Impact factor: 5.081

Review 8. Drugs in development for relapsing multiple sclerosis.

Authors: Rehiana Ali; Richard St John Nicholas; Paolo Antonio Muraro
Journal: Drugs Date: 2013-05 Impact factor: 11.431

Review 9. Alemtuzumab: a review of efficacy and risks in the treatment of relapsing remitting multiple sclerosis.

Authors: Cristina Guarnera; Placido Bramanti; Emanuela Mazzon
Journal: Ther Clin Risk Manag Date: 2017-07-14 Impact factor: 2.423

9 in total